Cost of illness analysis of Human Immuno-deficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) in a developing economy
Main Article Content
Abstract
Background: Highly Active Antiretroviral Therapy is for lifetime of the patients from time of diagnosis of HIV/AIDS. This translates into a substantial cost in drug therapy to the patients, government and donor agencies.
Objective: To conduct cost of illness analysis of HIV/AIDS in a Developing Economy in 2016.
Methods: A one-year retrospective review of 2560 prescriptions of 396 HIV/AIDS patients' case notes from January to December, 2016 obtained by systematic random sampling from 4800 case-notes of subjects that participated in this study was conducted. Sampling Interval =10 A data collection form was designed and used to collect data generated from the selected case notes. Cost of Illness was determined by prevalence rate method, using direct costs only.
Results: The annual cost of illness for the 396 HIV/AIDS patients on highly active antiretroviral therapy was ?40,674,760 (US$127,108.3) with drug, diagnostic/monitoring tests, transport, care/support and personnel cost components of ?25,479,760; US$79,624.3 (62.64%), ?7,200,000; US$22,500 (17.71%), ?1,440,000; US$4,500(3.54%), ?2,880,000; US$9,000 (7.08%) and ?3,675,000; US$11484 (9.03%) respectively. The annual average cost of illness of HIV/AIDS was ?102,714.04 (US$320.98)
Conclusion: The annual average cost of illness of HIV/AIDS represent 97% of annual per capita income. This is enormous. The Annual National cost of illness for HIV/AIDS in Nigeria, a developing economy may be about N590 billion annually.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Share
References
1. Mladovsky P, Srivastava D, Cylus J, Karanikolos M, Evetovits T, Thomson S and McKee M (2012). Health policy in the financial crisis. Eurohealth 18(1): 1–44.
2. Sulaiman S (2005). Rich nation, poor citizens: The missing links for increasing output and alleviating poverty in Nigeria. African Economic Analysis. Available online: http://www.africaeconomicanalysis.org/articles/gen/rich_nation.html
3. Drummond MF (1992). Cost of illness studies: a major headache. Pharmacoeconomics 2: 1–4.
4. World Health Organization (2009). HIV/AIDS implementation meeting presentation by Kevin M. De Cock, Director of HIV/AIDS Department. Question and Answer Archives. http://www.who.int/features/com.Revision of WHO ART guideline
5. Mondal MNI and Shitan M (2013). Factors affecting the HIV/AIDS epidemic: an ecological analysis of global data. African Health Sciences 13(2): 301–310.
6. Araoye MO (2004). Sample size determination. In: Araoye MO (Ed.), Textbook of Research Methodology with Statistics for Health and Social Scientists. Nathadex, Ilorin, Nigeria, pp. 117–120.
7. Lalonde RJ (1986). Evaluating the econometric evaluations of training programs with experimental data. The American Economic Review 76(4): 604–620.
8. Giwa A and Tayo F (2014). Cost-effectiveness analysis of anti-diabetic therapy in a university teaching hospital. International Journal of Pharma Sciences and Research 5(3): 82–91.
9. Federal Ministry of Health (2004). Guidelines for the use of antiretroviral (ARV) drugs in Nigeria. Abuja, Nigeria, pp. 1–59.
10. Greenspan JS, Greenspan D and Winkler JR (1988). Diagnosis and management of the oral manifestation of HIV infection and AIDS. Infectious Disease Clinics of North America 2: 373–383.
11. Sangeorzan JA and Bardy SF (1994). Epidemiology of oral candidiasis in HIV-infected patients; colonization, infection, treatment and emergence of fluconazole resistance. American Journal of Medicine 97(4): 339–346.
12. British National Formulary (2012). Use of fluconazole in fungal infections. Pharmaceutical Press, 70th revised edition (2015), Section 13.10.2.
13. UNAIDS (2017). Report on global AIDS epidemic: Western and Central Africa overview. World Health Organization, Geneva, pp. 76–978.
14. National Population Commission (NPC) (2011). Nigerian updated census population figure report, pp. 1–8.
15. Chang SM and Hong JP (2012). Economic burden of depression in southern Korea. Social Psychiatry and Psychiatric Epidemiology 47(5): 683–689.
16. Romley JA, Juday T and Solomon MD (2014). Early HIV treatment led to life expectancy gains valued at $80 for people infected in 1996–2009. Health Affairs (Millwood) 33(3): 370–377.
17. Federal Ministry of Health (2004). Guidelines for the use of antiretroviral (ARV) drugs in Nigeria. Abuja, Nigeria, pp. 1–59.
18. United Nations Development Programme (2016). Poverty situation bulletin. pp. 1–21.
19. Santos SP, Amando CAE and Santos MF (2012). Assessing the efficiency of mother-to-child HIV prevention in low and middle income countries using data envelopment analysis. Health Care Management Science 15(3): 206–222.